Objectives: Our objective was to evaluate the effect of Montelukast on the symptoms of asthma and allergic rhinitis (AR), assess its effect on the individual quality of life (QoL), and estimate the proportion of participants having adverse effects. Methods: This prospective, open-label study conducted at Dow University of Health Sciences, Ankle Saria Hospital and Sindh Government Hospital Liaquatabad, Karachi, from August 2018 to September 2019, included patients aged 18 years with a clinical diagnosis of Asthma, AR, or both. Patients were given a 10 mg Montelukast tablet each day and then called for follow-up in the fourth week, where the questions related to the improvement in the symptoms of asthma or AR were asked. Patients were also asked about the improvement in QoL and any adverse effects. Results: A total of 694 patients were registered of which 138(19.8%) had AR, 294(42.4%) had asthma, while 273(39.3%) had both. Mean age was 41.1±14.63 years and 352 (50.7%) were male and 342(49.3%) were females. On a follow-up visit, there was a sufficient improvement in 351 asthmatics (63.9%), and 288 patients with AR (70.1%) overall, strong or marked improvement in the day (n=342,62.3%) and night time (n=331,60.3%) asthma symptoms. Overall improvements in QoL were very good or good in 419 patients. Montelukast was well-tolerated here with adverse effects (like abdominal discomfort, fever, fatigue, headache, rash, and upper respiratory tract symptoms) seen in 125 patients (18.01%). Conclusion: Montelukast was very effective in improving the symptoms and QoL of the individuals suffering from asthma and/or AR. doi: https://doi.org/10.12669/pjms.36.7.2657 How to cite this:Zuberi FF, Haroon MA, Haseeb A, Khuhawar SM. Role of Montelukast in Asthma and Allergic rhinitis patients. Pak J Med Sci. 2020;36(7):---------. doi: https://doi.org/10.12669/pjms.36.7.2657 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
展开▼
机译：目的：我们的目标是评估孟鲁斯特蒙特利亚斯特对哮喘和过敏性鼻炎症状（AR）的影响，评估其对个体生活质量（QOL）的影响，并估计有不良反应的参与者的比例。方法：在健康科学的道琼斯大学，踝莎莉亚医院和信德政府医院Liaquatabad，卡拉奇进行的，从2018 8 - 9月2019年这项前瞻性，开放性研究，包括患者年龄> 18岁临床诊断为哮喘，AR的，或两者。患者每天给予10毫克蒙特洛尔司司，然后在第四周调用后续行动，其中询问了与哮喘或AR症状有关的问题。还询问患者的提高和任何不良影响。结果：共登录了694名患者，其中138例（19.8％），294（42.4％）哮喘，而273（39.3％）均为两者。平均年龄为41.1±14.63岁，352名（50.7％）是男性，342（49.3％）是女性。在随访，有351名哮喘患者（63.9％）和288例AR（70.1％）的整体，在天（N = 342,62.3％）强或明显改善和晚上的时间足够的改善（ n = 331,60.3％）哮喘症状。在419名患者中，QOL的整体改进非常好或良好。 Montelukast在这里有不良反应（如腹部不适，腹部不适，发烧，疲劳，头痛，皮疹和上呼吸道症状）在125名患者（18.01％）。结论：孟鲁斯特非常有效地改善患有哮喘和/或AR的个体的症状和QoL。 doi：https://doi.org/10.12669/pjms.36.7.2657如何引用这个：Zuberi FF，Haroon Ma，Haseeba，Khuhawar SM。蒙特利亚斯特在哮喘和过敏性鼻炎患者的作用。 Pak J Med Sci。 2020; 36（7）：---------。 DOI：https://doi.org/10.12669/pjms.36.7.2657这是一个开放式访问文章，根据Creative Commons归因许可证（http://creativecommons.org/licenses/by/3.0）分发只要正确引用原始工作，允许在任何媒体中不受限制使用，分发和再现。
展开▼
